TNFRSF17 and plasma cell myeloma: Adult patients with relapsed or refractory multiple myeloma who had previously received at least 3 prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and had not received prior BCMA-targeted therapy.